Compare MGRC & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGRC | ADPT |
|---|---|---|
| Founded | 1979 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | 1995 | 2019 |
| Metric | MGRC | ADPT |
|---|---|---|
| Price | $120.88 | $25.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $141.50 | $17.78 |
| AVG Volume (30 Days) | 148.8K | ★ 2.7M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.67% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $944,235,000.00 | $276,976,000.00 |
| Revenue This Year | $4.69 | $3.98 |
| Revenue Next Year | $4.81 | $22.72 |
| P/E Ratio | $48.54 | ★ N/A |
| Revenue Growth | 3.65 | ★ 54.77 |
| 52 Week Low | $94.99 | $11.93 |
| 52 Week High | $127.63 | $26.16 |
| Indicator | MGRC | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 56.80 | 66.99 |
| Support Level | $104.36 | $15.08 |
| Resistance Level | $121.81 | N/A |
| Average True Range (ATR) | 3.25 | 1.32 |
| MACD | 0.18 | 0.12 |
| Stochastic Oscillator | 72.26 | 90.49 |
McGrath RentCorp is a diversified business-to-business rental company with three rental divisions: relocatable modular buildings, portable storage containers, and electronic test equipment. It comprises four reportable business segments, namely the Modular Building segment (Mobile Modular), which generates maximum revenue; the Portable Storage segment (Portable Storage); the Electronic Test Equipment segment (TRS-RenTelco); and its classroom manufacturing business (Enviroplex), which sells modular buildings used as classrooms in California. The company generates its revenues mainly from the rental of its equipment under operating leases, with sales of equipment occurring in the normal course of business.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.